May 22nd 2023
Patients with higher platelet or neutrophil counts or platelet/lymphocyte ratios and systemic immune/inflammation index scores were more resistant to conventional systemic agents.
Managed Care Considerations and Implementation Strategies for Biosimilars in Oncology
1.0 Credit / Biosimilars, Oncology
View More
2022 ASH Annual Meeting Coverage—Recent Developments in Diffuse Large B-Cell Lymphoma: Insights and Application for Managed Care
1.0 Credit / Oncology
View More
Advances in High-Risk Myelodysplastic Syndromes: Insights and Application for Managed Care With ASH Annual Meeting Coverage
1.0 Credit / Hematology, Oncology
View More
Managed Care Insights on Optimizing the Use of BCMA-Targeted Treatments in Multiple Myeloma
1.5 Credits / Hematology, Oncology
View More
ESMO Congress 2022: Advances and Best Practices for Managed Care Pharmacists in the Treatment of Metastatic Head and Neck Squamous cell Carcinoma
1.0 Credit / Oncology
View More
Advances in Prostate Cancer: An Evidence-based Review for Managed Care Professionals
1.0 Credit / Oncology, Urology
View More
An Article in the American Journal of Managed Care’s Evidence-Based Oncology: Navigating the Complexities of Frontline Immunotherapy in NSCLC
2 Credits / Oncology, Respiratory
View More
Clinical Conversations With the Cancer Care Team: Discussing the Impact of Social Inequities on Treatment Outcomes in Triple-Negative Breast Cancer
1.5 Credits / Oncology, Women's Health
View More
PARAGLIDE-HF Offers Further Insight into Sacubitril/Valsartan in Heart Failure with Elevated EF
May 22nd 2023Presented at ESC HFA 2023, results of PARAGLIDE-HF detail the effects of sacubitril/valsartan on NT-proBNP and multiple clinical outcomes, relative to valsartan alone, in patients with HFmrEF or HFpEF.
Patients with Psoriatic Arthritis Report Greater Impact on Life than Rheumatoid Arthritis Patients
May 20th 2023An analysis of patient-reported outcomes data from more than 15,000 people with rheumatic disease sheds light on the apparent differences in impact on quality of life between psoriatic arthritis and rheumatoid arthritis.
FDA Committee Votes Against Risk-Benefit Profile of OCA 25 mg for NASH
May 20th 2023The June 22, 2023 PDUFA date for obeticholic acid 25 mg oral tablets for the treatment of precirrhotic liver fibrosis appears to be in jeopardy after a May 23, 2023 meeting of the FDA's Gastrointestinal Drugs Advisory Committee.
No Link Found Between Mental Health, Sleep Quality, and COVID-19 Vaccine Response
May 19th 2023The study revealed that healthcare workers with psychiatric disorders had slightly lower Anti-SARS-CoV-2-Spike IgG levels before their third COVID-19 vaccination, but this effect was mediated by age and body mass index.